Corcept Therapeutics has received FDA approval for its ovarian cancer drug Lifyorli. Lifyorli is the first drug of its kind from Corcept to be approved for this indication. It will be prescribed in combination with nab-paclitaxel. The treatment is intended for ovarian cancer patients who have relapsed one to three times. The FDA approval represents a significant step in the treatment of recurrent ovarian cancer.